Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas

Clinical Endocrinology

Volumn 77, Issue 1, 2012, Pages 139-145

  Müssig, Karsten ^a,b   Wehrmann, Tobias ^a   Dittmann, Helmut ^a   Wehrmann, Manfred ^a   Ueberberg, Bianca ^c,e   Schulz, Stefan ^d   Bares, Roland ^a   Petersenn, Stephan ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Kaiserswerther Diakonie   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADULT; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862012471     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04343.x     Document Type: Article

References (35)

1. Greco, A., Borrello, M.G., Miranda, C. et al. (2009) Molecular pathology of differentiated thyroid cancer. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 53, 440-453.
2. Pacini, F., Castagna, M.G., Brilli, L. et al. (2009) Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20(Suppl 4), 143-146.
3. Mazzaferri, E.L. & Jhiang, S.M. (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 97, 418-428. (Pubitemid 24345593)
4. Ain, K.B., Taylor, K.D., Tofiq, S. et al. (1997) Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. Journal of Clinical Endocrinology and Metabolism 82, 1857-1862. (Pubitemid 127495200)
5. Money, S.R., Muss, W., Thelmo, W.L. et al.(1989) Immunocytochemical localization of estrogen and progesterone receptors in human thyroid. Surgery 106, 975-978.
6. Aydin, O., Yildiz, L., Kefeli, M. et al. (2008) CD117 expression in normal, neoplastic, inflammatory, and reactive lesions of the thyroid. Pathology, Research and Practice 204, 359-365.
7. Yasuda, M., Ogane, N., Hayashi, H. et al.(2005) Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncology Reports 14, 1499-1504.
8. Erickson, L.A., Jin, L., Wollan, P.C. et al. (1998) Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Modern Pathology 11, 169-174. (Pubitemid 28144152)
9. Sobin, L.H., Gospodarowicz, M.K. & Wittekind, C. (2009) UICC:TNM Classification of Malignant Tumors, 7th edn. Wiley-Blackwell, Oxford.
10. Unger, N., Serdiuk, I., Sheu, S.Y. et al.(2008) Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clinical Endocrinology 68, 850-857. (Pubitemid 351703940)
11. Fischer, T., Doll, C., Jacobs, S. et al. (2008) Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. Journal of Clinical Endocrinology and Metabolism 93, 4519-4524. (Pubitemid 352789555)
12. Remmele, W. & Stegner, H.E. (1987) [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8, 138-140.
13. Tallini, G., Garcia-Rostan, G., Herrero, A. et al.(1999) Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. American Journal of Surgical Pathology 23, 678-685. (Pubitemid 29262831)
14. Tisell, L.E., Oden, A., Muth, A. et al.(2003) The Ki67 index a prognostic marker in medullary thyroid carcinoma. British Journal of Cancer 89, 2093-2097. (Pubitemid 38030908)
15. Vilar, E., Salazar, R., Perez-Garcia, J. et al. (2007) Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocrine-Related Cancer 14, 221-232. (Pubitemid 47242624)
16. Forssell-Aronsson, E.B., Nilsson, O., Bejegard, S.A. et al.(2000) 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. Journal of Nuclear Medicine 41, 636-642.
17. Druckenthaner, M., Schwarzer, C., Ensinger, C. et al.(2007) Evidence for Somatostatin receptor 2 in thyroid tissue. Regulatory Peptides 138, 32-39. (Pubitemid 44918128)
18. Klagge, A., Krause, K., Schierle, K. et al. (2010) Somatostatin receptor subtype expression in human thyroid tumours. Hormone and Metabolic Research 42, 237-240.
19. Garin, E., Devillers, A., Le Cloirec, J. et al.(1998) Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. European Journal of Nuclear Medicine 25, 687-694. (Pubitemid 28377030)
20. Waldherr, C., Schumacher, T., Pless, M. et al.(2001) Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nuclear Medicine Communications 22, 673-678.
21. Lamszus, K., Meyerhof, W. & Westphal, M. (1997) Somatostatin and somatostatin receptors in the diagnosis and treatment of gliomas. Journal of Neuro-Oncology 35, 353-364. (Pubitemid 27511138)
22. Ciampi, R., Vivaldi, A., Romei, C. et al.(2008) Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Molecular and Cellular Endocrinology 291, 57-62.
23. Broecker-Preuss, M., Sheu, S.Y., Worm, K. et al.(2008) Expression and mutation analysis of the tyrosine kinase c-kit in poorly differentiated and anaplastic thyroid carcinoma. Hormone and Metabolic Research 40, 685-691.
24. Natali, P.G., Berlingieri, M.T., Nicotra, M.R. et al.(1995) Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Research 55, 1787-1791.
25. Tanaka, T., Umeki, K., Yamamoto, I. et al.(1995) c-Kit protooncogene is more likely to lose expression in differentiated thyroid carcinoma than three thyroid-specific genes: thyroid peroxidase, thyroglobulin, and thyroid stimulating hormone receptor. Endocrine Journal 42, 723-728.
26. Arber, D.A., Tamayo, R. & Weiss, L.M. (1998) Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Human Pathology 29, 498-504. (Pubitemid 28213470)
27. Murakawa, T., Tsuda, H., Tanimoto, T. et al. (2005) Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. Pathology International 55, 757-765. (Pubitemid 43110201)
28. Ha, H.T., Lee, J.S., Urba, S. et al.(2010) A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20, 975-980.
29. van Hoeven, K.H., Menendez-Botet, C.J., Strong, E.W. et al. (1993) Estrogen and progesterone receptor content in human thyroid disease. American Journal of Clinical Pathology 99, 175-181. (Pubitemid 23059034)
30. Jaklic, B.R., Rushin, J. & Ghosh, B.C. (1995) Estrogen and progesterone receptors in thyroid lesions. Annals of Surgical Oncology 2, 429-434.
31. Kumar, A., Klinge, C.M. & Goldstein, R.E. (2010) Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. International Journal of Oncology 36, 1067-1080.
32. Davies, L. & Welch, H.G. (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295, 2164-2167.
33. Hoelting, T., Siperstein, A.E., Duh, Q.Y. et al. (1995) Tamoxifen inhibits growth, migration, and invasion of human follicular and papillary thyroid cancer cells in vitro and in vivo. Journal of Clinical Endocrinology and Metabolism 80, 308-313.
34. Khalil, A.B., Trudel, M. & Creel, R. (2010) Papillary carcinoma of the thyroid with fibromatosis like stroma: case report and review of literature. Endocrine Practice 16, 650-655.
35. Ringel, M.D. (2009) Molecular markers of aggressiveness of thyroid cancer. Current Opinion in Endocrinology, Diabetes, and Obesity 16, 361-366.